In 2011, Linden et al. demonstrated that estrogen receptor blocking agents (tamoxifen and fulvestrant) decreased FES tumor uptake to a greater extent compared to estrogen concentration lowering agents (aromatase inhibitors) [80]. The gene discussed is ESR1; the disease is neoplasm.